BioSpace News Archive

Exscientia plc (Nasdaq: EXAI) today announced that members of management will participate in the following upcoming investor conferences in March.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), today announced that it has entered into an exclusive option and license agreement (the “Agreement”) with Eterna Therapeutics Inc. (“Eterna”) for the development of novel beta 2 microglobulin (B2M)-deficient induced pluripotent stem cell (iPSC) lines, which Lineage will evaluate for development into differentiated cell transplant therapies.

Spectrum Solutions today announced the U.S. Food and Drug Administration (FDA) has granted 510(k) Class II clearance to the SDNA Saliva Collection Device as a microbial nucleic acid storage and stabilization device.

Trinity Biotech plc announced its entry into an increased loan facility to fund potential acquisitions and ongoing operations.

JanOne will present data on two of its investigational pharmaceutical compounds at the American Society of Interventional Pain Physicians (ASIPP) annual meeting in Washington DC in March, 2023.

NanoVibronix, Inc., a medical device company utilizing the Company’s proprietary and patented low intensity surface acoustic wave technology, announced that it intends to launch a month to month rental program on March 1, 2023 for its lead products, PainShield and UroShield.

Procyrion, Inc. announced today successful treatment of the first patients in the A PRIORI (Aortix therapy for Perioperative ReductIon Of Renal Injury) pilot trial to evaluate the performance of its Aortix™ percutaneous mechanical circulatory support (pMCS) device in preventing acute kidney injury (AKI) during cardiac surgery, a common and serious complication that impacts approximately 30% of patients.

Researchers at Children’s Hospital Los Angeles have received a nearly $1 million K08 grant from the National Institutes of Health —as well as funding from the U.S. Department of Defense—to support studies into diffuse intrinsic pontine glioma, a childhood brain tumor with a 0% survival rate.

Adolore Biotherapeutics, Inc. (“Adolore” or the “Company”) a biotechnology company focused on developing breakthrough opioid-free pain relieving (analgesic) treatments for pain, today announced that Dr. Roy C. Levitt, the Company’s founder, and Executive Chairman, will present at the 4th Annual NIH HEAL Initiative Investigator Meeting taking place February 21-22, 2023.

Sanara MedTech Inc. Based in Fort Worth, Texas, Sanara MedTech Inc. (“Sanara,” the “Company,” “we,” “our” or “us”) (NASDAQ: SMTI) announced today certain unaudited preliminary results for the fourth quarter and full-year 2022.